Free tool
FAERS Monitor: Inpefa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216203 or its brand name (Inpefa, Sotagliflozin). Reports on generic versions are filed under their own applications.
Reports
557
Serious
202
36% of reports
Hospitalization
108
Death reported
50
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness54
- diarrhoea50
- death47
- therapy interrupted37
- dyspnoea28
- off label use27
- product use issue27
- urinary tract infection25
- headache23
- nausea19
- fungal infection17
- drug ineffective15
- fatigue15
- vomiting15
- malaise14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 45 |
| 2024 | 296 |
| 2025 | 146 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,602 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 37 | 19.6 | 14.3 | 635 |
| fungal infectionSignal | 17 | 19.3 | 12.1 | 277 |
| urinary tract infectionSignal | 25 | 5.5 | 3.8 | 89 |
| product use issueSignal | 27 | 5.4 | 3.8 | 94 |
| dizzinessSignal | 54 | 4.1 | 3.2 | 126 |
| diarrhoeaSignal | 50 | 2.9 | 2.2 | 63 |
| deathSignal | 47 | 2.1 | 1.6 | 26 |
| dyspnoea | 28 | 1.9 | 1.3 | 11 |
| headache | 23 | 1.4 | 0.9 | 2 |
| malaise | 14 | 1.2 | 0.7 | 0 |
| vomiting | 15 | 1.2 | 0.7 | 0 |
| off label use | 27 | 1.2 | 0.8 | 0 |
| nausea | 19 | 0.9 | 0.6 | 0 |
| fatigue | 15 | 0.7 | 0.4 | 1 |
| drug ineffective | 15 | 0.4 | 0.3 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.